Efficacy and safety of new oral anticoagulants as part of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Data from an observational study

Aim To study efficacy and safety of a triple antithrombotic therapy with direct oral anticoagulants (DOAC) versus warfarin in patients with atrial fibrillation after acute coronary syndrome, for 12 months following discharge from the hospital.
Materials and methods This single-site cohort, prospective, observational study performed at the Regional Vascular Center 2 of the N.A. Semashko Nizhniy Novgorod Regional Clinical Hospital included 402 patients. It was possible to maintain contacts with 206 patients for 12 months. These patients were divided into two groups, the DOAC treatment (n=105) and the warfarin treatment (n=101) as a part of triple antithrombotic therapy upon discharge. Clinical observation was performed at 1, 3, 6, and 12 months after the discharge by structured telephone interview. Predetermined efficacy endpoints included cardiovascular death, myocardial infarction, stent thrombosis, and ischemic stroke. Safety endpoints included bleeding defined as small, medium (clinically significant), and major in accordance with the TIMI classification.
Results At 12 months of follow-up, 80 patients (76.19%) continued taking DOAC and 39 patients (38.61%, p<0.001) continued taking warfarin; in this process, only 25 patients (24.75%) monitored their INR on a regular basis. With a regular INR monitoring and TTR >70%, death rate did not differ in the warfarin and the DOAC treatment groups. However, there was a difference in reaching the composite efficacy endpoint (p=0.048): ischemic events occurred statistically significantly more frequently in the warfarin treatment group than in the DOAC treatment group.
Conclusions In 12 months after discharge from the hospital, compliance with the DOAC treatment as a part of the antithrombotic therapy was significantly higher than compliance with the warfarin treatment. The triple antithrombotic therapy with DOAC was safer than the warfarin treatment by the number of hemorrhagic complications and more effective in prevention of ischemic events, primarily due to no need for monitoring of lab test values.

1. Goldberg RJ, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: A community-wide perspective. American Heart Journal. 2002;143(3):519–27. DOI: 10.1067/mhj.2002.120410

2. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation. 2000;101(9):969–74. PMID: 10704162

3. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Journal of the American College of Cardiology. 1997;30(2):406–13. DOI: 10.1016/S0735-1097(97)00194-0

4. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. American Heart Journal. 2000;140(6):878–85. PMID: 11099991

5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines on management of atrial fibrillation developedin collaboration with EACTS. Russian Journal of Cardiology. 2017;22(7):7–86. DOI: 10.15829/1560-4071-2017-7-7-86

6. Moiseev S.V. Choice of antiplatelet/anticoagulation treatmentafter acute coronary syndrome in patients with atrial fibrillation. Clinical pharmacology and therapy. 2019;27(1):18–25. DOI: 10.32756/0869-5490-2019-1-18-25

7. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2016;133(11):1135–47. DOI: 10.1161/CIR.0000000000000336

8. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N et al. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. Archives of Internal Medicine. 2010;170(16):1433–1441. DOI: 10.1001/archinternmed.2010.271

9. Olesen JB, Sorensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace. 2015;17(2):187–93. DOI: 10.1093/europace/euu225

10. Kaidalova N.A., Koroleva L.Yu., Nosov V.P., Volkova A.T., Koryazina A.M., Kovalyova G.V. et al. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome. Russian Journal of Cardiology and Cardiovascular Surgery. 2019;12(2):141–5. DOI: 10.17116/kardio201912021141

11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139–51. DOI: 10.1056/NEJMoa0905561

12. Ezekowitz MD, Cappato R, Klein AL, Camm AJ, Ma C-S, Le Heuzey J-Y et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. American Heart Journal. 2014;167(5):646–52. DOI: 10.1016/j.ahj.2013.12.024

13. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma C-S, Le Heuzey J-Y et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. European Heart Journal. 2014;35(47):3346–55. DOI: 10.1093/eurheartj/ehu367

14. Wood S. Apixaban Noninferior to Warfarin in AF Patients: ARISTOTLE. 2011. [Internet] 2011. Available at: http://www.medscape.com/viewarticle/745190

15. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. The New England Journal of Medicine. 2017;377(16):1513– 24. DOI: 10.1056/NEJMoa1708454

16. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013;128(3):237–43. DOI: 10.1161/CIRCULATIONAHA.112.001139

17. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine. 2019;380(16):1509–24. DOI: 10.1056/NEJMoa1817083

18. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for CardioThoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35(37):2541–619. DOI: 10.1093/eurheartj/ehu278

19. Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V et al. ESC/EACTS recommendations for myocardial revascularization 2014. Russian Journal of Cardiology. 2015;20(2):5–81. DOI: 10.15829/1560-4071-2015-02-5-81

20. Roffi M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP et al. ESC guidelines for the management of patients with acute coronary syndrome without persistent St segment elevation 2015. Russian Journal of Cardiology. 2016;21(3):9–63. DOI: 10.15829/1560-4071-2016-3-9-63

21. Study Group Esc. The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Russian Journal of Cardiology. 2018;23(5):103–58. DOI: 10.15829/1560-4071-2018-5-103-158

22. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

23. Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet. 2013;381(9872):1107–15. DOI: 10.1016/S0140-6736(12)62177-1

24. Fox KAA. Dual or single antiplatelet therapy with anticoagulation? The Lancet. 2013;381(9872):1080–1. DOI: 10.1016/S0140-6736(13)60054-9

25. Mehta SR. Refining Antithrombotic Therapy for Atrial Fibrillation and Acute Coronary Syndromes or PCI. New England Journal of Medicine. 2019;380(16):1580–1. DOI: 10.1056/NEJMe1902214

26. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. The Lancet. 2019;394(10206):1335–43. DOI: 10.1016/S0140-6736(19)31872-0

27. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal. 2018;39(19):1726–1735a. DOI: 10.1093/eurheartj/ehy162

28. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2018;39(3):213–60. DOI: 10.1093/eurheartj/ehx419

29. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87–165. DOI: 10.1093/eurheartj/ehy394

30. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C et al. Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation. Chest. 2004;126(6):1938–45. DOI: 10.1378/chest.126.6.1938

31. O’Donnell M, Oczkowski W, Fang J, Kearon C, Silva J, Bradley C et al. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. The Lancet Neurology. 2006;5(9):749–54. DOI: 10.1016/S1474-4422(06)70536-1

32. Shlyakhto E.V. Cardiology. National guide. 2-nd edition. -M.: GEOTAR-Media;2015. - 800 p. ISBN 978-5-9704-2845-0